FOXL1 overexpression is associated with poor outcome in patients with glioma

Chen,Ainian; Zhong,Lingling; Lv,Jia

doi:10.3892/ol.2019.10351

FOXL1 overexpression is associated with poor outcome in patients with glioma

Authors:
- Ainian Chen
- Lingling Zhong
- Jia Lv
View Affiliations

Affiliations: Department of Neurology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China, Department of Neurosurgery, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: May 13, 2019 https://doi.org/10.3892/ol.2019.10351
Pages: 751-757
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas are the most common primary tumors in adult central nervous system and result in disappointing survival outcomes. FOXL1, as a transcription factor, plays an important role in regulating the expression of genes involved in cell metabolism, proliferation and differentiation. In this study, we investigated the relationship between FOXL1 expression and prognosis of patients with glioma. We selected 611 glioma patients from The Cancer Genome Atlas (TCGA) database and 132 glioma patients from Huai'an First People's Hospital (PFHH). The prognostic values of FOXL1 in glioma were analyzed in both cohorts. In TCGA cohort, the median (10.2389) was used as the cut‑off value of FOXL1 mRNA levels in tumor tissue. Kaplan‑Meier analysis showed that higher WHO glioma grade (P<0.001) and expression of FOXL1 (P<0.001) were associated with worse overall survival (OS). The univariate Cox regression model revealed that age (P<0.001), WHO grade (P<0.001), histological type (P<0.001) and FOXL1 expression (P<0.001) were associated with prognosis of glioma patients. In PFHH cohort, expression of FOXL1 in tumor cells was detected by immunohistochemistry (IHC) staining based on a tissue microarray (TMA) sample. Kaplan‑Meier analysis also showed that WHO glioma grade (P<0.001) and expression of FOXL1 (P=0.012) were associated with OS in glioma patients. The univariate Cox regression showed that WHO grade (P=0.001), histological type (P<0.001) and FOXL1 expression (P=0.013) were associated with prognosis of glioma patients. In both cohorts Kaplan‑Meier subgroup analyses showed FOXL expression correlated with OS in high WHO grade subgroup, while low grade subgroup showed no such correlation. This study showed that higher expression of FOXL1 is associated with poor OS of glioma patients in TCGA and PFHH cohorts. Especially, FOXL1 overexpression is associated with worse outcomes in high WHO grade subgroup. Our findings suggest that FOXL1 expression is a candidate predictor of clinical outcome in glioma patients and may act as an effective molecular marker for immunotherapeutic strategies of glioma patients in clinical practice.

View Figures

View References

1	Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
3	Cheng YS, Lin C, Cheng YP, Yu YL, Tang CT and Hueng DY: Epithelial cell transformation sequence 2 is a potential biomarker of unfavorable survival in human gliomas. Neurol India. 62:406–409. 2014. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor, Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y and Rose S: Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: Toward clinical translation. Semin Nucl Med. 45:136–150. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lam EW, Brosens JJ, Gomes AR and Koo CY: Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer. 13:482–495. 2013. View Article : Google Scholar : PubMed/NCBI
7	Lehmann OJ, Sowden JC, Carlsson P, Jordan T and Bhattacharya SS: Fox's in development and disease. Trends Genet. 19:339–344. 2003. View Article : Google Scholar : PubMed/NCBI
8	Carter ME and Brunet A: FOXO transcription factors. Curr Biol. 17:R113–R114. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Ahmad A, Li Y, Banerjee S, Kong D and Sarkar FH: Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
10	Qin Y, Gong W, Zhang M, Wang J, Tang Z and Quan Z: Forkhead box L1 is frequently downregulated in gallbladder cancer and inhibits cell growth through apoptosis induction by mitochondrial dysfunction. PLoS One. 9:e1020842014. View Article : Google Scholar : PubMed/NCBI
11	Takano-Maruyama M, Hase K, Fukamachi H, Kato Y, Koseki H and Ohno H: Foxl1-deficient mice exhibit aberrant epithelial cell positioning resulting from dysregulated EphB/EphrinB expression in the small intestine. Am J Physiol Gastrointest Liver Physiol. 291:G163–G170. 2006. View Article : Google Scholar : PubMed/NCBI
12	Perreault N, Sackett SD, Katz JP, Furth EE and Kaestner KH: Foxl1 is a mesenchymal modifier of Min in carcinogenesis of stomach and colon. Genes Dev. 19:311–315. 2005. View Article : Google Scholar : PubMed/NCBI
13	Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP: FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res. 73:5416–5425. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ertao Z, Jianhui C, Chuangqi C, Changjiang Q, Sile C, Yulong H, Shirong C and Hui W: Low level of FOXL1 indicates a worse prognosis for gastric cancer patients. Tumour Biol. 37:11331–11337. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yang FQ, Yang FP, Li W, Liu M, Wang GC, Che JP, Huang JH and Zheng JH: Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer. Int J Clin Exp Pathol. 7:110–122. 2013.PubMed/NCBI
16	Nakada C, Satoh S, Tabata Y, Arai K and Watanabe S: Transcriptional repressor foxl1 regulates central nervous system development by suppressing shh expression in zebra fish. Mol Cell Biol. 26:7246–7257. 2006. View Article : Google Scholar : PubMed/NCBI
17	Jiang YZ, Yu KD, Zuo WJ, Peng WT and Shao ZM: GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer. 120:1329–1337. 2014. View Article : Google Scholar : PubMed/NCBI
18	Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q and Cai S: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 15:552016. View Article : Google Scholar : PubMed/NCBI
19	Ueno H, Jones AM, Wilkinson KH, Jass JR and Talbot IC: Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 53:581–586. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kaestner KH, Silberg DG, Traber PG and Schütz G: The mesenchymal winged helix transcription factor Fkh6 is required for the control of gastrointestinal proliferation and differentiation. Genes Dev. 11:1583–1595. 1997. View Article : Google Scholar : PubMed/NCBI
21	Kaestner KH, Bleckmann SC, Monaghan AP, Schlöndorff J, Mincheva A, Lichter P and Schütz G: Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development. Development. 122:1751–1758. 1996.PubMed/NCBI
22	Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, Michaux L, Sagaert X, Marynen P, Hagemeijer A, et al: FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia. 19:1299–1305. 2005. View Article : Google Scholar : PubMed/NCBI
23	Streubel B, Vinatzer U, Lamprecht A, Raderer M and Chott A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 19:652–658. 2005. View Article : Google Scholar : PubMed/NCBI
24	Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W and Dong JT: FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res. 66:6998–7006. 2006. View Article : Google Scholar : PubMed/NCBI
25	Halmos B, Bassères DS, Monti S, D'Aló F, Dayaram T, Ferenczi K, Wouters BJ, Huettner CS, Golub TR and Tenen DG: A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res. 64:4137–4147. 2004. View Article : Google Scholar : PubMed/NCBI
26	Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
27	Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI